Auxilium Pharmaceuticals has received marketing approval from the FDA for Xiaflex (collagenase clostridium histolyticum), a first in class, orphan-designated, biologic for the treatment of adult Dupuytren’s contracture patients with a palpable cord. The company expects to begin shipping the drug to its distribution partners in early March for the planned launch in late March. Auxilium will market Xiaflex in the U.S. and has established a distribution network that will allow health care ...